Recent Updates
Recently added Catalysts
TLPH Positive Sentiment

Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 13, 2026

Key Takeaway: Talphera, Inc. will announce its first quarter 2026 financial results on May 13, 2026, followed by a live webcast and conference call. Investors can dial in to participate in the discussion of the results and business updates. Talphera's lead product, Niyad®, is recognized for its potential as an anticoagulant and has received Breakthrough Device Designation from the FDA, highlighting the company's focus on innovative therapies.
Price reaction · baseline $0.8701 (2026-05-06 close) · hit after-hours · clean, no other TLPH news in the window
day 0 close
+0.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • Talphera is set to release its financial results, indicating ongoing operational activities.
  • The company is focused on innovative therapies, showcasing a commitment to research and development.
  • Receiving Breakthrough Device Designation status for Niyad® reflects regulatory recognition of Talphera's potential impact.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+222%
120-day peak, hindsight
Typical move
22.4%
average across 2 past catalysts
Cash runway
~13 mo
Low dilution risk
Lead asset
sufentanil
Phase 3 · Moderate-to-severe Acute Pain

Full Press Release Details

SAN MATEO, Calif., May 7, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release first quarter 2026 financial results after market close on Wednesday, May 13, 2026, then host a live webcast and conference call at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss the results and provide an update on the Company's business.
The webcast can be accessed here or by visiting the Investors section of the Company's website at www.talphera.com and clicking on the webcast link posted within Investors/News & Events/Upcoming Events section. The webcast will include a slide presentation and a replay will be available on the Talphera website for 90 days following the event.
Conference Call Information
Investors who wish to participate in the conference call may do so by dialing 1-800-836-8184 for North American callers, or 1-646-357-8785 (toll applies) for international callers outside of Canada. The conference ID is 24180.
About Talphera, Inc.
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera's lead product candidate, Niyad® is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA).
This release is intended for investors only. For additional information about Talphera, please visit www.talphera.com.

Frequently Asked Questions

When will Talphera announce its Q1 2026 financial results?

Talphera will release its Q1 2026 financial results on May 13, 2026.

How can I access Talphera's financial webcast?

You can access the webcast via the Investors section on Talphera's website.

What is Talphera's lead product candidate?

Talphera's lead product candidate is Niyad®, a formulation of nafamostat.

What designation has Niyad® received from the FDA?

Niyad® has received Breakthrough Device Designation from the FDA.

What is the conference call number for investors?

Investors can dial 1-800-836-8184 to join the conference call.

Last updated: May 7, 2026